Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kissei Files Rigel’s AML Drug Olutasidenib in Japan
Kissei Pharmaceutical said on May 27 that it has filed a new drug application in Japan for olutasidenib for relapsed or refractory acute myeloid leukemia (AML) with susceptible isocitrate dehydrogenase-1 (IDH1) mutations. Olutasidenib is an IDH1 inhibitor designed to bind…
To read the full story
Related Article
- Kissei Sublicenses Taiwan Rights for Rigel’s AML Drug to OEP
May 11, 2026
- Kissei Snares Rigel’s AML Therapy in Japan, Korea, Taiwan
September 5, 2024
BUSINESS
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
June 17, 2026
- Astellas CEO’s Pay Rises to 733 Million Yen in FY2025: Securities Report
June 17, 2026
- Torii Starts PIII Trial of Cantharidin for Common Warts
June 17, 2026
- Ono CEO’s Pay Climbs to 260 Million Yen
June 16, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…